Comparative Pharmacology
Head-to-head clinical analysis: CHANTIX versus NICOTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHANTIX versus NICOTINE.
CHANTIX vs NICOTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at α4β2 nicotinic acetylcholine receptors; also full agonist at α7 nicotinic receptors. Reduces nicotine craving and withdrawal symptoms while blocking nicotine's reinforcing effects.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
1 mg orally twice daily after starting a 1-week titration: days 1-3: 0.5 mg once daily; days 4-7: 0.5 mg twice daily; day 8 onward: 1 mg twice daily.
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
None Documented
None Documented
Clinical Note
moderateNicotine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nicotine resulting in a loss in efficacy."
Clinical Note
moderateTerminal elimination half-life is approximately 24 hours. Clinical context: Steady-state is achieved within 4 days; significant accumulation occurs in renal impairment (creatinine clearance <30 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
Renal: 81% unchanged, 8% as metabolites; Fecal: <10% (as metabolites); Biliary: minimal.
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Category C
Category C
Smoking cessation aid
Smoking cessation aid
Nicotine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Nicotine."